Cingulate to Participate in Benzinga All Live Access Event
14 avr. 2023 14h00 HE
|
Cingulate Inc.
KANSAS CITY, Kan., April 14, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
TILT Holdings Announces April Conference Schedule
04 avr. 2023 07h30 HE
|
TILT Holdings Inc.
PHOENIX, April 04, 2023 (GLOBE NEWSWIRE) -- TILT Holdings Inc. (“TILT” or the “Company”) (NEO: TILT) (OTCQX: TLLTF), a global provider of cannabis business solutions that include inhalation...
Cingulate Completes First Cohort of Phase 3 Adult Onset and Duration Trial of CTx-1301 (dexmethylphenidate) for ADHD
04 avr. 2023 06h45 HE
|
Cingulate Inc.
Trial On Track for 3Q 2023 Results Pivotal Phase 3 Trial in Pediatric/Adolescent Patients Planned to Begin Mid-2023 KANSAS CITY, Kan., April 04, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:...
Mobiquity Technologies Unveils ATOS 2.0: A New and Improved Privacy-Centric Advertising Platform
23 mars 2023 08h30 HE
|
Mobiquity Technologies, Inc.
NEW YORK, March 23, 2023 (GLOBE NEWSWIRE) -- Mobiquity Technologies, Inc. (NASDAQ: MOBQ) (the “Company”), a leading provider of next-generation data intelligence and advertising technologies,...
Mobiquity Adds Industry Veteran, Brett Perloff, to Head-Up Revenue in Anticipation of New Product Launch
16 mars 2023 08h30 HE
|
Mobiquity Technologies, Inc.
NEW YORK, March 16, 2023 (GLOBE NEWSWIRE) -- Mobiquity Technologies, Inc. (NASDAQ: MOBQ) (the “Company”), a leading provider of next-generation data intelligence and advertising technologies, today...
Cingulate and Indegene Announce Joint Commercialization Agreement for Lead ADHD Candidate CTx-1301
13 mars 2023 06h45 HE
|
Cingulate Inc.
Go-to-Market Solution Provides Full Commercial Support for the First, True Entire Active-Day Medication Designed to treat ADHD Indegene Model Geared for Efficient National Commercial Launch in...
Cingulate Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical and Business Update
10 mars 2023 16h05 HE
|
Cingulate Inc.
CTx-1301 Phase 3 Adult Dose-Optimization Study Ongoing; Results Expected 3Q 2023 Positive Top-Line Data from CTx-1301 Fed/Fast Study Announced, Full Results Submitted for Presentation at Forthcoming...
Mobiquity Technologies Launches Mobi-AI Engine for Digital Advertising
01 mars 2023 08h45 HE
|
Mobiquity Technologies, Inc.
NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- Mobiquity Technologies, Inc. (NASDAQ: MOBQ) (the “Company”), a leading provider of next-generation data intelligence and advertising technologies, has...
Cingulate Announces Positive Top-Line Results from Fed/Fast Study of Lead Asset CTx-1301 for ADHD
23 févr. 2023 16h30 HE
|
Cingulate Inc.
Primary Endpoints Demonstrate CTx-1301 Can be Taken With or Without Food CTx-1301 is Designed as a True, Entire Active-Day Treatment for ADHD KANSAS CITY, Kan., Feb. 23, 2023 (GLOBE NEWSWIRE) --...
SGLY Class Action Deadline Alert: Johnson Fistel Encourages Shareholders to Submit Their Losses
10 janv. 2023 07h54 HE
|
Johnson Fistel, LLP
SAN DIEGO, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of investors of Singularity Future...